Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Aichi Cancer Center Hospital, Nagoya

Hirosaki University Hospital, Hirosaki

National Cancer Center Hospital East, Kashiwa

The Jikei University Kashiwa Hospital, Kashiwa

Shikoku Cancer Center, Matsuyama

Ehime University Hospital, Tōon

Kurume University Hospital, Kurume

Kure Medical Center and Chugoku Cancer Center, Kure

Hokkaido University Hospital, Sapporo

Sapporo Medical University Hospital, Sapporo

Hyogo Cancer Center, Akashi

Kansai Rosai Hospital, Amagasaki

Iwate Medical University Hospital, Morioka

Tokai University Hospital, Isehara

Nippon Medical School Musashi Kosugi Hospital, Kawasaki

Mie University Hospital, Tsu

Tohoku University Hospital, Sendai

University of the Ryukyus Hospital, Nakagami-gun

Kindai University Hospital, Sayama

Saitama Medical University International Medical Center, Hidaka

Shizuoka Cancer Center, Nagaizumi-cho

National Cancer Center Hospital, Chuo-ku

Cancer Institute Hospital, Koto-ku

The Jikei University Hospital, Minato-ku

Toho University Omori Medical Center, Ōta-ku

Keio University Hospital, Shinjuku-ku

Chiba Cancer Center, Chiba

Chiba University Hospital, Chiba

Gifu University Hospital, Gifu

Kagoshima City Hospital, Kagoshima

Kyoto University Hospital, Kyoto

Nagasaki University Hospital, Nagasaki

Niigata University Medical & Dental Hospital, Niigata